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Abstract
AIM
To detect chronic hepatitis B (CHB), chronic hepatitis 
C (CHC) and human immunodeficiency virus (HIV) in-
fections in dried blood spot (DBS) and compare these 
samples to venous blood sampling in real-life.
METHODS
We included prospective patients with known viral 
infections from drug treatment centers, a prison and 
outpatient clinics and included blood donors as negative 
controls. Five drops of finger capillary blood were 
spotted on filter paper, and a venous blood sample was 
obtained. The samples were analyzed for HBsAg, anti-
HBc, anti-HBs, anti-HCV, and anti-HIV levels as well 
as subjected to a combined nucleic acid test (NAT) for 
HBV DNA, HCV RNA and HIV RNA.
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ORIGINAL ARTICLE
Dried blood spots, valid screening for viral hepatitis and 
human immunodeficiency virus in real-life
Prospective Study
Belinda K Mössner, Benjamin Staugaard, Janne Jensen, Søren Thue Lillevang, Peer B Christensen, 
Dorte Kinggaard Holm
RESULTS
Samples from 404 subjects were screened (85 CHB, 
116 CHC, 114 HIV and 99 blood donors). DBS had a 
sensitivity of > 96% and a specificity of > 98% for 
the detection of all three infections. NAT testing did 
not improve sensitivity, but correctly classified 95% 
of the anti-HCV-positive patients with chronic and 
past infections. Anti-HBc and anti-HBS showed low 
sensitivity in DBS (68% and 42%).
CONCLUSION
DBS sampling, combined with an automated analysis 
system, is a feasible screening method to diagnose 
chronic viral hepatitis and HIV infections outside of the 
health care system.
Key words: Dried blood spot; Real-life; Screening; 
Hepatitis B; Hepatitis C; Human immunodeficiency 
virus; People who inject drugs; Drug-users; Prisoners
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This study shows that it is feasible to combine 
serology and nucleic acid screening for hepatitis 
B virus (HBV), hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV) infections in one dried 
blood sample (DBS) collected in real life and analyzed 
using a modern laboratory platform. We observed a 
sensitivity and specificity of > 96% for HBV, HCV, and 
HIV and correctly classified 95% of all HCV patients into 
past vs  chronic infections compared to simultaneously 
collected venous blood samples. The study confirms 
that DBSs are feasible samples in outreach clinics and 
confirms the high sensitivity and specificity of previous 
laboratory-based studies.
Mössner BK, Staugaard B, Jensen J, Lillevang ST, Christensen 
PB, Holm DK. Dried blood spots, valid screening for viral 
hepatitis and human immunodeficiency virus in real-life. World 
J Gastroenterol 2016; 22(33): 7604-7612  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i33/7604.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v22.i33.7604
INTRODUCTION
Chronic viral hepatitis B (CHB) and C (CHC) represent 
a major health burden worldwide, with approximately 
350 million and 170 million people infected, res­
pectively[1]. Persistent infection may progress to end­
stage liver disease and hepatocellular carcinoma, and 
primary liver cancer is now the second leading cause 
of cancer death worldwide[2].
In Denmark, as in most western countries, drug 
users have the highest prevalence of chronic hepatitis 
C[3,4]. Still, a Danish register­based study showed that 
the majority of drug users(67%) have never been 
tested[5].
The existing literature indicates a wide range 
of barriers for testing that are related to both the 
individual patient (e.g., lack of knowledge, not feeling 
sick, fear of invasive tests, and distrust of the medical 
system) and the healthcare provider system (e.g., 
no access to basic medical care or a lack of specific 
medical care in substance user treatment centers)[6­11].
In Denmark, chronic Hepatitis B and HIV infections 
are highly prevalent among men who have sex 
with men, sex workers and immigrants from highly 
endemic countries. These groups also have difficulties 
accessing the existing health system and may have 
poor knowledge of the diseases and risk factors[12].
A recent Danish study has shown that the large 
majority of HIV patients are successfully managed in 
the existing health system; however, new interventions 
are needed to improve care for immigrants and drug 
users[13]. 
Easy access to serological testing for Hepatitis C 
and non­invasive methods to diagnose liver fibrosis 
have improved the screening rates among drug 
users. In the era of the new treatment regimens for 
hepatitis C with direct­acting antivirals (DAA) with 
few side effects and a short treatment duration, it has 
now become feasible to test and treat the drug­user 
population[14­16].
Dried blood samples on filter paper (DBS) were 
originally used to screen for neonatal phenylketonuria[17]. 
Since then, the method has been evaluated and used 
with increased frequency, e.g., antibody testing for 
a wide range of infectious diseases, particularly in 
resource­limited settings[18­21].
Recently, it was shown that DBS can be combined 
with automatic analysis on a modern analysis platform 
(e.g., Abbott Architect), allowing high throughput 
testing at a reasonable price[22,23]. However, in most 
of these studies, venous whole blood was used for 
the DBS samples instead of capillary blood, and the 
performance and feasibility of “real life” DBS testing in 
this set­up is, to our knowledge, not well described.
Objectives
The objective of this study was to determine and 
compare the sensitivity of DBS from capillary blood to 
whole plasma when the DBS sampling was obtained 
in real life settings and analyzed at a modern high 
throughput diagnostic laboratory using an automated 
analytic platform.
The study was conducted from September 2014 
to September 2015. Combined NAT screening for 
HIV RNA, HBV DNA and HCV RNA was performed 
using the Procleix Ultrio Elite assay from Grifols 
(Grifols Diagnostic Solutions, Allschwil, Switzerland), 
and serological screening for HIV, HBV and HCV was 
performed using Abbott Architect assays (Abbott 
Diagnostics, Delkenheim, Germany) .
The study was conducted in the region of southern 
Denmark. 
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Patients had a known HBV, HCV or HIV infection, 
and attended either the Outreach Clinics in the Drug 
Treatment Center or state prison in Nyborg or the 
Outpatient Clinic at the Hospital to be eligible for 
inclusion. Patients were informed about the study 
at previously planned visits. If they were willing to 
participate, they were included with due consideration 
time.
Due to the relatively low prevalence of HIV and HBV 
infections among Danish drug users and prisoners, 
paired EDTA plasma samples/DBS were obtained 
from these patients at the Departments of Infectious 
Diseases at, Odense University Hospital and Lillebaelt 
Hospital, Kolding. Samples from Hepatitis C­infected 
patients were obtained from drug treatment centers 
and the prison. According to the power estimation, 
optimally, 100 patients with each infection should be 
included, corresponding to an overall 30% prevalence 
of the tested markers, which is comparable to the 
30%­40% prevalence of HCV infection in the target 
drug­using population. In addition, paired EDTA plasma 
samples/DBS were obtained from 99 blood donors who 
were negative for all three viruses from the blood bank 
at Odense University Hospital. 
The DBS and EDTA plasma samples were collected 
simultaneously in most cases, but up to 10 d was 
allowed between the two samples.
MATERIALS AND METHODS
All samples were analyzed at the Department of 
Clinical Immunology, Odense University Hospital. Five 
spots on a Whatman® 903 protein saver card (Sigma­
Aldrich, Copenhagen, Denmark) were each covered 
with a large drop of capillary blood (approximately 
75 μL) from the fingertip(s) of the patient/donor and 
subsequently dried at room temperature for at least 
24 h and up to 5 d to prepare the DBS. 
The approximate volume of 75 μL of whole blood 
in each dried blood spot was based on preliminary 
studies where different amounts of exact volumes 
of whole blood were added to the Whatman® 903 
protein saver card. We found that 75 μL was the 
amount needed to fill a single spot on the Whatman 
filter paper. In the real-life study, the intention was to 
fill each of the 5 spots using their visual appearance, 
thereby approximating a volume of 75 microliters in 
each spot.
We compared the test results for all viruses in DBS 
samples that had dried for 24 h or for up to 7 d at 
room temperature using the NAT test to validate the 
stability and found no difference (data not shown). 
Each of the dried blood spots was eluted with 1000 
μL of a buffer (PBS/0.05% Tween 20/0.08% sodium 
azide) overnight at room temperature on a shaker, 
followed by centrifugation of the eluate for two mi­
nutes at 10000 rpm. Except for the discriminatory 
NAT analysis, all laboratory analyses were performed 
immediately after centrifugation of the eluates. The 
average estimated DBS sample dilution was 1:23 
compared to plasma.
The DBS eluates and the corresponding plasma 
samples were tested for the presence of anti­HIV, 
anti­HCV, hepatitis B surface antigen, anti­HBc and 
anti­HBs with the Architect HIV Ab/Ag, Architect HCV 
Ab, Architect HBsAg, Architect HBs Ab and Architect 
HBc Ab assays using the Architect system (Abbott 
Diagnostics, Delkenheim, Germany). In addition, all 
samples were tested with the Procleix Ultrio Elite assay 
using the Procleix Panther System (Grifols Diagnostic 
Solutions, Allschwil, Switzerland). The Ultrio Elite assay 
is a qualitative nucleic acid amplification test (NAT) 
for the simultaneous detection of HIV­1/2 RNA, HCV 
RNA and HBV DNA. The detection limits (at the 95% 
confidence level) for the Ultrio Elite assay are 18.0 
IU/mL (HIV­1­RNA), 3.0 IU/mL (HCV­RNA) and 4.3 
IU/mL (HBV­DNA), according to the package insert. For 
samples that were reactive in the initial NAT analysis, 
an additional discriminatory NAT was performed for 
HIV­1/2 RNA (Ultrio Elite dHIV), HCV RNA (Ultrio 
Elite dHCV), and HBV DNA (Ultrio Elite dHBV). The 
initially reactive samples were stored at ­20 °C for 
1­5 d before the discriminatory NAT was performed. 
All plasma samples were analyzed according to the 
manufacturer’s instructions.
A quantitative nucleic acid amplification test was 
performed using the COBAS® AmpliPrep/COBAS® 
TaqMan® 48 system (Roche Diagnostics, Basel, Swit­
zerland) to quantify the viral load in plasma samples 
that were positive for either HIV RNA, HCV RNA or 
HBV DNA in the Ultrio Elite assay. The COBAS® Ampli­
Prep/COBAS® TaqMan® HIV­1 Test, v2.0, COBAS® 
AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, 
v2.0 and COBAS® AmpliPrep/COBAS® TaqMan® HBV 
Test, v2.0 assays were used, and all the quantita­
tive analyses were performed according to the 
manufacturer’s instructions. The lower detection limit 
for the Cobas TaqMan assays described above was 
slightly higher than the NAT according to the package 
insert: 20 copies/mL (HIV), 15 IU/mL (HCV) and 20 
IU/mL (HBV).
Statistical analysis
The DBS results were compared with plasma, 
which was used as the gold standard to assess 
the sensitivity, specificity, positive predictive value, 
negative predictive value and receiver operating 
characteristics curve (ROC­curve) of the DBS results. 
Descriptive statistics were shown as the means, 
medians and interquartile ranges, with the minimum 
and maximum values reported, as appropriate. A 
confidence interval of 95% was used. All data analysis 
was performed using STATA 14 IC software (Statacorp 
LP, College Station, TX).
Sample size and power estimation: With an 
expected prevalence of 33% (100 positive and 200 
negative tests for all markers, except the HBs antibody), 
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viremia by DBS was not reliable because a significant 
proportion (16% and 98%) of these patients had very 
low viral loads as result of antiviral treatment.
Hepatitis C
Among the 116 known HCV­infected patients, all were 
plasma anti­HCV­positive and 112 (96.6%) were 
also DBS anti­HCV­positive (Figure 1). The four DBS­
negative patients were all HCV­RNA­negative in both 
plasma and DBS, indicating a past infection. Among 
the plasma anti­HCV­positive patients, 73.3% (85/116) 
were plasma NAT­positive, indicating an ongoing 
infection. Of these patients, 95.3% (81/85) were also 
DBS NAT­positive, and 100% (85/85) of the active 
infections were anti­HCV­positive in the DBS. 
The four patients who were plasma HCV RNA­
positive and DBS­negative had a viral load < 100 
IU/mL (range 0­95), and two of these were on DAA 
treatment. One patient was plasma NAT­negative, but 
weakly DBS-positive, corresponding to a specificity of 
99.5% (193 DBS/194 plasma) for the NAT. 
Hepatitis B
Among the 85 known HBV­infected patients, 83 were 
both plasma­ and DBS­positive for HBsAg, one was 
only positive in plasma and one was negative in both 
plasma and DBS (Figure 2). The patient who was 
HBsAg­positive in plasma and negative in DBS had a 
quantitative plasma HBsAg level below 175 IU/mL. 
This patient was under treatment for HBV infection 
and HBV DNA was positive in both plasma and DBS. 
The patient who was HBsAg­negative in both plasma 
and DBS was also under treatment for HBV. HBV DNA 
was positive in plasma, but below the LLOQ, anti­
HBc and anti­HBs were positive in both plasma and 
DBS, suggesting seroconversion. All 71 untreated CHB 
an observed agreement of 95% between DBS and 
plasma samples would correspond to 5 false negative 
and 10 false positive results for each marker. More than 
12 false negative and 20 false positive samples would 
lead to a rejection of the 95% agreement between the 
venous blood sample and DBS.
Ethical considerations: All patients signed written 
informed consent before inclusion in the study. The 
Danish Research Ethics Committee approved the study 
(Project­ID: S­20140128).
RESULTS
Corresponding plasma samples and DBS were ob­
tained from the 404 subjects included in the study: 
114 HIV­infected, 85 hepatitis B­infected, 116 hepatitis 
C­infected and 99 blood donors. The blood donors 
were all negative for the 3 infections (Table 1).
The overall performance of the serology markers 
for anti­HCV, anti­HIV and HBsAg had a sensitivity of > 
96% and a specificity >99% for all three markers. In 
contrast, a lower sensitivity for anti­HBc and anti­HBs 
was observed (Table 2). 
After combining all analyses, we correctly classified 
98.0% (396/404) of patients for all 3 infections and 
99.3% of all serological tests (1204/1212) using DBS, 
with 6 false negative (4 anti­HCV, 1 HBsAg and 1 anti­
HIV) and 2 false positive (HBsAg) results. One patient 
with hepatitis B was HBsAg­negative in both plasma 
and DBS. Thus, the addition of NAT identified 1 (HBV) 
patient who would have been missed by serological 
testing alone. However, the overall advantage of 
adding NAT to the analysis was that 95% of Hepatitis C 
patients were correctly classified into ongoing vs past 
infection groups. For HBV and HIV, the classification of 
IQR: Interquartile range [expressed as IU/mL (HBV and HCV) and copies/mL (HIV)]. HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV: Human 
immunodeficiency virus.
Table 1  Descriptive summary and characteristics of viral infections
Viral infection Total, n Mono- + Co-infected, n N with quantitative 
analysis
Median IQR (25-75)
Blood donors   99 0 NA
HBV   85 78 + 5 HIV + 2 HCV   78       144 19-2780
HCV 116 111 + 3 HIV + 2 HBV 105 225000 4300-1110000
HIV 114 106 + 5 HBV + 3 HCV 112           0 0-19
Table 2  Sensitivity and specificity of serological testing by Abbott Architect of dried blood spots compared to plasma samples
Plasma, n DBS, n Sensitivity (%) Specificity (%)
(95%CI)
ROC PPV NPV
Negative Positive Negative Positive (95%CI)
Anti-HCV 288 116 292 112 96.6 (91.4; 99.1) 100.0 (98.7; 100) 0.98 100.0% 98.6%
HBsAg 318   86 319   85 96.5 (90.1; 99.3)   99.4 (97.7; 99.9) 0.98   97.6% 99.1%
Anti-HBc 232 172 286 118 68.0 (60.5; 74.9)   99.6 (97.6; 100) 0.84   99.2% 80.8%
Anti-HBs 246 158 337   67 42.4 (34.6; 50.5) 100.0 (98.5; 100) 0.71 100.0% 73.0%
Anti-HIV 289 115 290 114 98.3 (93.9; 99.8)   99.7 (98.1; 100) 0.99   99.1% 99.3%
ROC: Area under the receiver operating curve; PPV: Positive predicting value; NPV: Negative predicting value.
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patients were HBsAg­positive by DBS.
Two participants without known HBV infections 
were (weakly) positive for HBsAg in DBS and negative 
in plasma; one was an HCV­infected patient and one 
was a blood donor. Both were anti­HBs­positive in 
plasma and NAT­negative in both plasma and DBS. A 
duplicate retest of the two DBS samples showed that 
they were HBsAg­negative; thus, we concluded that 
the first DBS test was a false positive test. 
A low sensitivity for anti­HBc (68%) and anti­HBs 
(42%) was observed. In 2/85 CHB patients, discrepant 
results for anti­HBc were observed, with positive 
plasma and negative DBS (CMIA­plasma 5.2­6.8 vs 
CMIA­DBS 0.3­0.4); both were HBsAg­positive and 
HBV DNA­negative.
Among the 91 anti­HBc­positive plasma samples 
from non­HBV infected patients, discrepant results 
were found in 53 samples in which the plasma was 
positive (CMIA median 6.19, range 1.1­10.1) and DBS 
was negative (CMIA median 0.295, range 0.06­0.99). 
Among the 53 discrepant DBS­negative results, 
one was co­infected with HIV/ HCV, 31 were anti­
HIV­positive, 19 were anti­HCV­positive, and 2 were 
negative for all other serological markers (blood 
donors).
In twelve out of 85 CHB patients, a discrepant result 
for the anti­HBs analysis was obtained. Anti­HBs was 
positive in plasma (1.08­9.44 mIU/mL), but negative in 
Figure 1  Flowchart for the test of hepatitis C patients.
Figure 2  Flowchart for the test of hepatitis B patients.
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the DBS (0­0.3 mIU/mL). However, all twelve patients 
were HBsAg­positive in both plasma and DBS. 
Among the 145 anti­HBs­positive plasma samples 
in non­HBV infected patients, discrepant results 
were observed in 79 patients in which the plasma 
was positive (median 9.9 mIU/mL, range 1­75) and 
the DBS was negative (median 0.01 mIU/mL, range 
0­0.93). Among the 79 discrepant DBS­negative 
results, one was co­infected with HIV/ HCV, 43 were 
anti­HCV­positive, 17 were anti­HIV­positive, and 
18 were negative for all other serological markers 
(blood donors). Vaccination status for Hepatitis B was 
not recorded in our study, but of the HBV­negative 
patients, 106 had protective anti­HBs titers (anti­HBs 
≥ 10 mIU/mL) in plasma compared to 28 in the DBS.
HIV
Among the 114 patients with known HIV infections, 
all were anti­HIV­positive in plasma, and 113 (99.1%) 
were also positive in the DBS (Figure 3). The one 
HIV­positive patient who was not detected using the 
DBS received antiretroviral treatment (ART) and had 
undetectable levels of the HIV­RNA in both plasma and 
DBS.
Furthermore, one blood donor was weakly anti­
HIV­positive in plasma (1.62/cut­off 1.0), but negative 
in the anti-HIV confirmatory test. The donor was also 
DBS anti­HIV­negative and NAT­negative in both 
plasma and DBS. 
Among the 114 anti­HIV­positive patients, 112 
were undergoing antiretroviral treatment. HIV­RNA 
was negative in both plasma and DBS from 54.9% of 
patients (62/113), 6.2% (7/113) were positive in both 
tests, and 38.9% (44/113) were HIV­RNA­positive in 
plasma and negative in DBS. Among these patients, 43 
received ART and had the following HIV­RNA levels: 20 
patients were below the LLD (lower limit of detection), 
15 were below the LLOQ (lower limit of quantification) 
and 8 patients had quantifiable HIV-RNA levels (range 
32­483 copies/mL). 
DISCUSSION
The use of DBS with a high throughput automated 
platform to screen for viral Hepatitis B, C and HIV 
showed acceptable agreement between the plasma 
and DBS tests for anti­HCV, anti­HIV and HBsAg in 
real­life settings. However, the overall sensitivity of 
anti­HBc and anti­HBs was low. There are several 
possible explanations for this observation, including the 
amount of blood used for the DBS samples was small 
and the addition of the eluate­buffer further diluted the 
sample 23­fold. In a study by Lee et al[24], DBS was 
prepared from venous blood samples, and they noted 
that the assay titers obtained from the DBS samples 
were generally lower than the titers obtained from the 
plasma samples. The authors suggested that different 
cut­off values should be used to validate tests that 
were positive in the DBS because the small amount of 
blood in the DBS led to lower assay titers. 
The low sensitivity for the serological markers 
anti­HBs and anti­HBc in DBS vs plasma observed 
in our study is in contrast to recent studies using 
automated platforms[22,23]. This observation may to 
some extent be caused by the different starting titers 
of the samples, resulting in different dilution factors by 
elution. The results are consistent with other studies, 
where low DBS sensitivities have been reported, 
ranging between 70% and 100%, with specificities 
from 94% to 100%[18,25,26]. In the study by Ross, 
almost perfect sensitivities and specificities for DBS 
were observed compared to serum samples; however, 
DBS were prepared by applying 100 μL of whole blood 
to generate DBS (Whatman filter paper), a procedure 
that most likely is not possible with DBS in real­world 
settings, where we estimated the average amount to 
be 75 μL. However, with this standardized method, 
allowances could be made for the dilution and a lower 
cut­off calculated for anti­HBs in DBS samples. When 
applying this cut­off, the sensitivity rose from 43% to 
54% in our study, which was still not acceptable (data 
not shown). 
We speculate that if an indicator for the amount 
of blood collected on the paper could be developed to 
ensure that enough blood is present for the analysis 
(e.g., weight, hemoglobin, visual guidance, etc.), it 
would also allow the calculation of a quantitative anti­
HBs level/mL of serum from DBS, enabling the method 
to be used in outreach vaccination trials. 
A study by Villar showed that a lower sampling 
volume led to more discordant results and emphasized 
that even though the sampling is relatively easy, care 
must be taken to ensure an adequate sample size[27]. 
We recommend that the visual inspection should be 
used to confirm that the circles of the filter paper have 
Figure 3  Flowchart for the test of human immunodeficiency virus patients. 
HIV: Human immunodeficiency virus; NAT: Nucleic acid test.
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been appropriately filled with blood when using DBS 
for routine screening. 
In our study population, only moderate agreement 
was observed for HBV DNA and HIV RNA by NAT, 
probably because a significant number of the included 
patients had very low viral loads as a result of antiviral 
therapy. Several studies have shown decreased 
sensitivity of DBS compared to plasma in samples with 
lower viral loads[20,28,29]. In our study, we estimated 
that the LLD was below 500 copies/mL for HIV­RNA, 
100 IU/mL for HCV­RNA and 200 IU/mL for HBV­DNA 
by DBS testing. This result may be partially explained 
by the 23­fold dilution of the DBS compared to plasma 
during preparation. However, this dilution is unlikely 
to be a significant problem when using DBS as a 
screening method in an untreated population. In this 
setting, viral loads below DBS cut­offs are rare, and all 
these patients will be positive by serology testing.
Our study has several limitations. As it is a real­life 
study, we did not know the volume of blood applied to 
the DBS filter paper (and we did not record whether 
the filter circles were appropriately filled with blood). 
Therefore, we cannot rule out the possibility that the 
discrepant results were due to a low sampling volume. 
Furthermore, due to the low prevalence of HIV and 
HBV in our target population, a significant number of 
the HBV­ and HIV­infected participants were recruited 
from the Department of Infectious Diseases and had 
low or undetectable viral loads as a result of antiviral 
treatment. However, as a screening tool, DBS will 
be used among treatment naïve patients, and in this 
population, DBS had 100% sensitivity, except for HBV 
patients in the latent phase, who will be detected by 
HBsAg. 
As for the 4 HCV patients who were anti­HCV­
positive but HCV RNA false negative in DBS, we 
suggest that patients who were categorized as having 
past HCV infection using DBS should have this result 
confirmed using a venous blood sample. 
As the NAT did not improve DBS sensitivity, it would 
have been more cost­effective to perform DBS testing 
as a two-step analysis: first screening with anti-HCV, 
anti­HIV and HBsAg, and then performing a NAT of 
samples that were positive in serology. Depending on 
the prevalence of infection, this strategy could save 
50%­95% of NATs and still identify > 95% of chronic 
infections. Some primary advantages of DBS are that 
screening of all three infections can be performed 
in one sample; the samples can be collected by on­
site personnel, ensuring correct person identification; 
and the samples may be sent by regular mail to the 
laboratory. These advantages enable “on­site” testing 
without the need for specialized personnel, and 
therefore, the test is both cheaper and more effective 
than the current methods used to identify patients with 
chronic viral hepatitis or HIV infections. 
In conclusion, the collection of DBS outside of the 
health care system, combined with an automated 
laboratory system for analysis, is a feasible method of 
screening for chronic viral hepatitis and HIV infections 
among drug users in prisons and other resource­
limited settings. 
In Danish guidelines, yearly screening in drug 
users is recommended; however, this test has been 
difficult to implement using venous blood sampling. 
Easy access to DBS testing enables large­scale 
implementation in difficult to reach populations. 
The identification of the infected patients is the first 
step to control these infections, and we suggest that 
national testing strategies should include DBS testing 
to improve the coverage of clinical care in these 
populations.
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